← All IPOs

Molbio Diagnostics IPO Price Band & Lot Size

MainboardListed
MOLBIO · · NSE

Updated · GMP, subscription and listing data refresh through the day.

Molbio Diagnostics IPO Details

RegistrarKFin Technologies Limited
Lead managersKotak Mahindra Capital Company Limited
Offer documentDraft (DRHP)
Fresh issue₹200 Cr
Offer for sale₹739.7 Cr
Market cap at the offer₹9,300 Cr

Market capitalisation is the post-issue share count in the offer document’s capital structure (11,52,39,996 shares) multiplied by the upper end of the price band, ₹807. It is arithmetic on those two filed figures, not a valuation.

Molbio Diagnostics Financials ₹ in crore

Revenue CAGR+31.5%2024 → 2026 · 2 yrs
Profit CAGR+40.2%2024 → 2026 · 2 yrs
Total assets CAGR+32.6%2024 → 2026 · 2 yrs
00%5005%100010%150015%200020%202420252026
₹ crore202420252026
Revenue₹836.56₹1,020.42₹1,445.69
Expenses———
Net profit (PAT)₹83.54₹138.58₹164.14
PAT margin10.0%13.6%11.4%
Total assets₹1,221.06₹1,461.56₹2,148.42

Molbio Diagnostics Shareholding before & after the IPO

Before the IPO
Pre-issue · RHP capital structure
46.65%
Promoter
After the IPO
Post-issue · as filed 14-AUG-2026
41.29%
Promoter
Promoter & promoter groupafter the IPO
Holding41.29%
Shares4,75,82,801
Through the IPO-5.36% · exiting

The founding owners and their group entities.

Breakdown as filed
Other Indian shareholders37.05%4,26,93,951
Individuals / HUF4.24%48,88,850

Post-issue pattern as filed with the NSE. Pre-issue register from the RHP capital structure, cross-checked against exchange data. Pre-issue percentages are taken from the disclosure, never estimated.

Molbio Diagnostics Anchor Investors largest allocation first

Anchor investors33named in the letter
Anchor book₹281.45 Crat ₹807 per share
Largest allocation8.88%GOLDMAN SACHS FUNDS - GOLD…
#Anchor investorShares% of book₹ Cr
1GOLDMAN SACHS FUNDS - GOLDMAN SACHS INDIA EQUITY PORTFOLIO3,09,7808.88%25.00
2NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA PHARMA FUND RCT-RPF2,47,8427.11%20.00
3INTERNATIONAL FINANCE CORPORATION*2,47,8427.11%20.00
4BLACKROCK GLOBAL FUNDS - INDIA FUND2,47,8427.11%20.00
5MIRAE ASSET HEALTHCARE FUND MIRAHCFD2,47,8427.11%20.00
6ICICI PRUDENTIAL QUALITY FUND1,85,8865.33%15.00
7ICICI PRUDENTIAL EXPORTS AND SERVICES FUND1,48,6984.26%12.00
8KOTAK CONTRA FUND1,44,5764.15%11.67
9KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK HEALTHCARE FUND1,44,5764.15%11.67
10KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK CONSUMPTION FUND1,44,5584.14%11.67
11HDFC MUTUAL FUND - HDFC PHARMA AND HEALTHCARE FUND1,38,0063.96%11.14
12MOTILAL OSWAL LARGE CAP FUND1,23,9303.55%10.00
13TATA INDIA PHARMA & HEALTHCARE FUND1,23,9303.55%10.00
14NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA INNOVATION FUND1,23,9123.55%10.00
15HDFC VALUE FUND1,08,4323.11%8.75
16HDFC MUTUAL FUND - HDFC INNOVATION FUND1,08,4143.11%8.75
17EDELWEISS TRUSTEESHIP CO LTD AC - EDELWEISS MF AC - EDELWEISS92,9342.66%7.50
18HDFC LIFE INSURANCE COMPANY LIMITED88,5972.54%7.15
19BAJAJ LIFE INSURANCE LIMITED88,5962.54%7.15
20WHITEOAK CAPITAL PHARMA AND HEALTHCARE FUND80,5682.31%6.50
21HDFC MUTUAL FUND - HDFC MNC FUND78,8582.26%6.36
22GOLDMAN SACHS ETF TRUST - GOLDMAN SACHS INDIA EQUITY ETF61,9741.78%5.00
23WHITEOAK CAPITAL AGGRESSIVE HYBRID FUND43,3621.24%3.50
24ISIF EQUITY LONG-SHORT FUND37,1701.07%3.00
25AXIS MAX LIFE INSURANCE LIMITED A/C SUSTAINABLE EQUITY FUND - ULIF02505/10/21SUSTAINEQU10435,1041.01%2.83
26AXIS MAX LIFE INSURANCE LIMITED A/C - ULIF00225/06/04LIFEBALANC104 - BALANCED FUND33,3670.96%2.69
27EDELWEISS TRUSTEESHIP CO LTD AC - EDELWEISS MF AC- EDELWEISS RECENTLY LISTED IPO FUND30,9960.89%2.50
28AXIS MAX LIFE INSURANCE LIMITED PENSION MAXIMISER FUND (ULIF01715/02/13PENSMAXIMI104)11,4010.33%0.92
29AXIS MAX LIFE INSURANCE LIMITED A/C UHG2S - INDIA CONSUMPTION OPPORTUNITIES FUND2,6250.08%0.21
30AXIS MAX LIFE INSURANCE LIMITED A/C UMFPH - HIGH GROWTH PENSION FUND2,6250.08%0.21
31AXIS MAX LIFE INSURANCE LIMITED A/C - ULGF00217/04/06GRATBALANC104 - GROUP GRATUITY BALANCED FUND1,7500.05%0.14
32AXIS MAX LIFE INSURANCE LIMITED PENSION PRESERVER FUND(ULIF01815/02/13PENSPRESER104)8620.02%0.07
33AXIS MAX LIFE INSURANCE LIMITED A/C - ULIF00625/11/05PENSBALANC104 - PENSION BALANCED FUND8620.02%0.07

Ranked by size of allocation; every anchor in an issue pays the same price, so the ranking is the same whether read in shares, rupees or share of the book. Anchor investors are allotted shares one day before the issue opens, at a price fixed on that day, and are locked in afterwards (30 days for half the allocation, 90 days for the rest). Read straight from the company’s own Anchor Allocation intimation letter filed with the exchanges — names appear exactly as printed there. Percentages are the filer’s own and total the anchor portion, not the whole issue. View the filed letter

Molbio Diagnostics IPO Lot Size & Minimum Investment by investor category

ApplicationSharesAmount at ₹807
Retail (min)1 lot18₹14,526
Retail (max)13 lots234₹1,88,838
sHNI (min)14 lots252₹2,03,364
bHNI (min)69 lots1,242₹10,02,294

One lot is 18 shares, so a single application at the ₹807 cut-off costs ₹14,526. Retail applications are capped at ₹2,00,000, which is 13 lots for this issue. Amounts are shown at the upper band because applications are made at the cut-off price.

Molbio Diagnostics IPO Strengths & Risks as disclosed in the DRHP

▲ Strengths (6)
The company is well-positioned to address unmet demand in a large and growing molecular diagnostic market with gaining credence of point-of-care testing.
The company has strong R&D capabilities and a track record of developing innovative diagnostic products.
The company has developed and commercialized a novel portable multi-disease point-of-care molecular diagnostics platform.
The company has a scalable business model with strong entry barriers, a high proportion of recurring revenues, and a growing suite of tests.
The company's strategic collaborations and acquisitions enhance its capabilities and offerings.
The company has a management team with deep domain expertise and a track record of delivering strong financial performance.
▼ Risk factors (8)
The company derives a significant portion of its revenues from sales to Indian central and state governments and international aid agencies, making it vulnerable to unfavorable policy changes or decreased funding.
A significant portion of the company's revenues is derived from the sale of diagnostic test kits for tuberculosis (TB), making it susceptible to declines in demand for these kits.
The company relies on its top 10 customers for a significant portion of its revenue, and the loss of these customers or a decline in demand could adversely affect its business.
The company's investments in R&D may not result in the successful development and government approval of new tests, which could adversely affect its business.
The company incurred losses in Fiscal 2023 and may incur losses in the future.
The company's sales cycle and sales demand are variable, making it difficult to forecast business results.
The company's inability to accurately forecast demand for its products and manage its inventory may adversely affect its business.
Product liability claims or regulatory actions could have an adverse effect on the company's business, financial condition, results of operations, and cash flows.

How to check Molbio Diagnostics IPO allotment status

Allotment is decided and published by the issue’s registrar, not by the exchange and not by alphave. For Molbio Diagnostics Limited, the registrar is KFin Technologies Limited — allotment is finalised in the days between the issue closing on 12 Aug 2026 and listing on 17 Aug 2026.

RegistrarKFin Technologies Limited
You will needPAN, application number or demat ID
Issue closes12 Aug 2026
Listing date17 Aug 2026
Issue opens
Mon, 10 Aug, 2026
Bidding 10:00 am – 5:00 pm IST
Issue closes
Wed, 12 Aug, 2026
Last day to bid · UPI mandate by 5:00 pm
Allotment finalisedTentative
Thu, 13 Aug, 2026
By KFin Technologies; check with PAN, application no. or DP ID
Refunds & UPI unblockTentative
Fri, 14 Aug, 2026
Unallotted amounts released · allotted shares credited to demat
Listing
Mon, 17 Aug, 2026
NSE · trading from 10:00 am IST

Allotment and refund dates follow SEBI’s T+3 listing timeline in trading days and are tentative until the registrar and the exchange confirm them. alphave does not hold allotment results — only the registrar can show whether an application was allotted.

The registrar publishes allotment on its own portal: KFintech. Your bank will also show the blocked amount released if shares were not allotted.

Molbio Diagnostics IPO Price Band & Lot Size FAQs

What is the price band of Molbio Diagnostics IPO?

The Molbio Diagnostics Limited IPO price band is ₹807 to ₹807 per share. Applications are made at the cut-off price, which is the upper end of the band.

What is the lot size of Molbio Diagnostics IPO?

One lot is 18 shares, so a single application at the ₹807 cut-off costs ₹14,526. Retail investors can apply for up to 13 lots within the ₹2,00,000 retail limit.

What is the minimum investment in Molbio Diagnostics IPO?

₹14,526 — one lot of 18 shares at ₹807. Bids in the non-institutional category start above ₹2,00,000 and are made in multiples of the lot.

Is Molbio Diagnostics IPO a mainboard or SME issue, and on which exchange?

Molbio Diagnostics Limited is a mainboard issue listing on NSE. The lead manager is Kotak Mahindra Capital Company Limited.

What is the issue size of Molbio Diagnostics IPO?

The issue size is ₹939.7 crore, of which ₹200 crore is a fresh issue and ₹739.7 crore an offer for sale by existing shareholders.

Molbio Diagnostics IPO Registrar where allotment and refund queries go

RegistrarKFin Technologies Limited

The registrar processes the allotment and the refunds. Contact details are as printed in the offer document; the exchange and your broker cannot change an allotment.

How to Apply for the Molbio Diagnostics IPO ASBA and UPI, as SEBI sets them

  1. Apply through your broker’s IPO window or your bank’s net banking (ASBA). The money stays in your own account and is only blocked until allotment.
  2. Choose the number of lots and bid at the cut-off price. Retail applications are capped at ₹2,00,000; above that the bid moves to the non-institutional category.
  3. If you applied through a broker, approve the UPI mandate in your payment app. The mandate must be approved by 5 pm on the day after your bid, and by 5 pm on the closing day for bids made on the last day (12 Aug 2026).
  4. One application per PAN. A second application under the same PAN is rejected, and both may be.
  5. After allotment the blocked amount is released for shares not allotted. Allotment and refund queries go to the registrar, KFin Technologies Limited, not to the exchange or the broker.

What is GMP in an IPO?

Grey Market Premium is the price at which an unlisted IPO application or share changes hands informally, before the stock is listed on the exchange. It is quoted as a rupee figure over the issue price: a premium of ₹120 on a ₹807 upper band means the grey market is dealing at ₹927.

The grey market is an over-the-counter market between private dealers. It is not operated or supervised by NSE, BSE or SEBI, no trade is settled through a clearing corporation, and no dealer is obliged to publish or honour a quote. Figures are collected by third-party reporters and different sources routinely disagree, which is why a premium can move sharply within a day or vanish entirely once bidding closes.

Grey Market Premium is an unofficial, unregulated over-the-counter datapoint reported by third parties. It is not a price, a forecast, or an indication of listing gains, and is not investment advice.